BERGENBIO ASA - Oral presentation to reveal data from trial evaluating bemcentinib in relapsed mesothelioma - - Trial-in-Progress poster to be presented regarding the BGBC016 1L STK11m NSCLC trial -BERGEN, Norway ,May 25, 2023 -BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Company will be presenting two abstracts at the 2023American Society of Clinical Oncology (ASCO) Annual Meeting inChicago June 2-6, 2023 . An oral presentation will highlight the results of MIST3, an investigator led, multi-center Phase IIa study led by ProfessorDean Fennell at the University ofLeicester, UK that assessed the use of bemcentinib in combination with pembrolizumab in patients with relapsed mesothelioma. A Trial-in-Progress poster will outline the plans for the ongoing BGBC016 Phase 1b/2a study evaluating bemcentinib in combination with pembrolizumab and chemotherapy in 1L STK11m NSCLC patients. The abstracts will be available in Scientific Presentations (https://www.bergenbio.com/investors/presentations/) on the Company's website shortly after their presentations at the conference. ASCO Abstract Details: Oral Presentation Title: Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy (https://meetings.asco.org/abstracts-presentations/222514) Abstract Number: 8511 Abstract Session:Lung Cancer Presenter:Matthew Krebs , Ph.D., FRCP,Christie Hospital ,Manchester, UK Date/Time: Monday 5th June,11.30am - 1.00pm Poster Presentation Title: Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation (https://meetings.asco.org/abstracts-presentations/226055) Abstract Number: TPS9154 Poster Number: 134b Abstract Session:Lung Cancer - Non-Small Cell Metastatic Presenter: Rajwanth Veluswamy, MD, MSCR,Mount Sinai, New York , NY Date/Time: Sunday 4th June8.00am-11.00am -End- ContactsMartin Olin CEO,BerGenBio ASA ir@bergenbio.comRune Skeie , CFO,BerGenBio ASA rune.skeie@bergenbio.com Investor RelationsGraham Morrell graham.morrell@bergenbio.com Media RelationsJan Lilleby jl@lillebyfrisch.no +47 90 55 16 98 AboutBerGenBio ASA BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.BerGenBio is based inBergen, Norway with a subsidiary inOxford, UK . The company is listed on theOslo Stock Exchange (ticker: BGBIO). For more information, visit?www.bergenbio.com Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source
